Question:

A patient with IgG4-related disease with pancreatitis initially responded to steroid therapy but experienced a relapse (gland size increased) after tapering. What is the next step in treatment?

Show Hint

IgG4-RD classically presents as autoimmune pancreatitis (Type 1), Mikulicz disease (salivary/lacrimal gland enlargement), or retroperitoneal fibrosis. The histology triad includes: 1) dense lymphoplasmacytic infiltrate, 2) storiform fibrosis, 3) obliterative phlebitis. Rituximab is the definitive steroid-sparing agent.
Updated On: Sep 3, 2026
  • High dose steroids
  • Rituximab
  • Methotrexate
  • dapsone
Show Solution
collegedunia
Verified By Collegedunia

The Correct Option is B

Solution and Explanation

Concept:
IgG4-Related Disease (IgG4-RD) is a systemic fibro-inflammatory condition that forms tumefactive lesions in various organs (commonly pancreas, salivary glands, retroperitoneum), characterized by dense lymphoplasmacytic infiltrates rich in IgG4-positive plasma cells and storiform fibrosis.
While highly responsive to glucocorticoids initially, relapses are common upon tapering.
Explanation:

• The first-line induction therapy for IgG4-RD is systemic glucocorticoids. The response is often rapid and dramatic. However, up to 40-50% of patients relapse when steroids are tapered or discontinued.

• B-cell depletion therapy is highly effective in IgG4-RD because B cells and plasmablasts are central to its pathogenesis. By depleting the B-cell precursors, the continuous supply of short-lived plasmablasts driving the disease is halted.

Rituximab (an anti-CD20 monoclonal antibody) is the preferred and most effective agent for steroid-refractory, relapsing, or high-risk IgG4-RD. It is the established next step to induce remission and act as a steroid-sparing agent.

• Option (A), High dose steroids, could temporarily treat the relapse, but restarting high-dose steroids without adding a steroid-sparing agent in a patient who already failed a taper is poor practice and leads to unacceptable glucocorticoid toxicity.

• Option (C), Methotrexate, and other conventional synthetic DMARDs (like Azathioprine or Mycophenolate) have been used, but their efficacy in IgG4-RD is variable and inferior to B-cell depletion. Rituximab is strongly preferred.

• Option (D), Dapsone, has no established role in the treatment of IgG4-RD.
Final answer:
Rituximab is the treatment of choice for relapsing IgG4-related disease after a steroid taper.
Was this answer helpful?
0
0

Top NEET SS Medical Questions

View More Questions

Top NEET SS Questions

View More Questions